SGLT-2抑制剂对糖尿病肾病影响的研究进展

Research progress of the effect of SGLT-2 inhibitors on diabetic nephropathy

糖尿病肾病(diabetic nephropathy,DN)是目前导致终末期肾病的常见原因。长期高血糖会引起肾脏代谢紊乱和血流动力学改变,加重糖尿病肾病进展。作为一种新型降糖药物,钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂在降低血糖之外有肾脏保护作用,主要表现为减少尿蛋白、调节脂代谢、减轻体重、降低血尿酸、降压等作用。其作用机制可能与抗氧化、抗炎、抗纤维化、改善肾脏高滤过等方面有关。SGLT-2抑制剂在使用过程中可能存在的不良反应包括泌尿生殖道感染和急性肾损伤等。因此,该文就SGLT-2抑制剂在防治DN中的相关研究进展进行综述。

Diabetic nephropathy(DN) is the common cause of end-stage renal disease.Long-term hyperglycemia can cause renal metabolic disorders and hemodynamic changes,which can aggravate the progression of diabetic nephropathy.As a new type of hypoglycemic drug,sodium-glucose cotransporter-2(SGLT-2) inhibitor has kidney protective effects in addition to its hypoglycemic effect,which mainly includes reducing urine protein,regulating lipid metabolism,reducing body weight,lowering blood uric acid and lowering blood pressure,etc.Its mechanism of action may be related to anti-oxidation,anti-inflammatory,anti-fibrosis,and the improvement of renal hyperfiltration,etc.The possible adverse reactions of SGLT-2 inhibitors during the use of it include urinary reproductive tract infections and acute kidney injury,etc.Therefore,this article reviews the related research progress of SGLT-2 inhibitors in the prevention and treatment of DN.